Nintedanib (Nintedanib) role and efficacy

Nintedanib(Nintedanib)marketed as Ofev and Vargatef is an oral drug used to treat idiopathic pulmonary fibrosis and with other drugs for certain types of non-small cell lung cancer. In March 2020, it was approved in the United States for the treatment of patients with progressive phenotype(characteristics)Chronic fibrosis(Scar)Interstitial lung disease(ILD).

Nintedanib is used to treat idiopathic pulmonary fibrosis, it has been shown to slow down forced vital capacity, it also improves people's quality of life, nintedanib does not improve the survival rate of IPF patients. It interferes with processes such as fibroblast proliferation, differentiation, and deposition of extracellular matrix. The National Institute for Health and Care Excellence (NICE) recommends the use of nintedanib in cases of IPF where the FVC is 50-80% of the predicted value. NICEadvises that if a person's FVC drops by 10% or more within 12 months, indicating that the disease is progressing despite treatment, treatment should be stopped.

A pooled analysis using extrapolation estimated that across six nintedanibtrials, the mean survival of nintedanib-treated patients was 11.6years and the mean survival of placebo-treated patients was 3.7years. In the current study, 78 patients died during the 3 years of follow-up, corresponding to a 3 annual survival rate of 59.4%. If you want to get more high-quality information, you can contact YaoDe. YaoDe will do its best to learn more about high-quality overseas drugs for you.